June 18 (Reuters) - A unit of Chinese investment firm CITIC Capital Holdings Ltd has offered to buy U.S.-listed biotech firm China Biologic Products Holdings Inc.
The unit, CCRE, offered $110 in cash for each share of China Biologic it does not already own, valuing the Cayman Islands-headquartered company at $3.65 billion. (https://bit.ly/2leBZGo)
As of June 8, CCRE owned a 5.1 percent stake in China Biologic. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)